Login
$ACTU
$0.53 +$0.05 (11.09%) Close

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Cash and cash equivalents
Prepaid assets and other current assets
Total current assets
Deferred offering costs
Deferred offering costs and other assets
Total assets
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Other accrued expenses
Related party convertible notes payable at fair value
Accrued compensation
Accrued interest, current
Total current liabilities
Long term liabilities:
Warrant liability
Accrued interest, less current portion
License payable
Total long-term liabilities
Total liabilities
Redeemable convertible preferred stock, $0.000001 par value; no shares authorized, issued or outstanding at December 31, 2024; 33,463,018 shares authorized and 24,678,355 shares issued and outstanding at December 31, 2023; aggregate liquidation value of $0 and $121,033,336 as of December 31, 2024 and 2023, respectively
Stockholders’ equity:
Preferred stock, $0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding
Common stock, $0.000001 par value, 200,000,000 shares authorized, 24,013,577 and 23,245,203 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated deficit
Total stockholders’ equity
Total liabilities and stockholders’ equity

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support